NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM): Preliminary results of multicenter phase II study
2008 ◽
Vol 26
(15_suppl)
◽
pp. 8099-8099
◽
2009 ◽
Vol 4
(1)
◽
pp. 97-101
◽